Randomized Trial: Ruxolitinib for the Treatment of Severe COVID-19

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial – Journal of Allergy and Clinical Immunology

Commentary: Multicenter RCT evaluating ruxolitinib (a JAK inhibitor) for COVID-19 – PulmCrit